최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Pediatric infection and vaccine: PIV, v.30 no.1, 2023년, pp.47 - 54
유혜선 (성균관대학교 삼성서울병원 소아청소년과) , 신아름 (성균관대학교 삼성서울병원 소아청소년과) , 김두리 (성균관대학교 삼성서울병원 소아청소년과) , 최재영 (성균관대학교 삼성서울병원 중환자의학과) , 주희영 (성균관대학교 삼성서울병원 소아청소년과) , 조중범 (성균관대학교 삼성서울병원 중환자의학과) , 강철인 (성균관대학교 삼성서울병원 내과) , 김예진 (성균관대학교 삼성서울병원 소아청소년과)
With the widespread use of broad-spectrum antibiotics in clinical practice, the emergence of multidrug-resistant (MDR) gram-negative bacteria has become a global problem. The MDR Pseudomonas aeruginosa infection is especially difficult to treat and increases mortality in critically ill patients. Cef...
World Health Organization. Antimicrobial resistance [Internet]. Geneva: World Health Organization;?2021 [cited 2022 Oct 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.?
O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. London:?Government of the United Kingdom, 2016.?
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a?systematic analysis. Lancet 2022;399:629-55.
Horcajada JP, Montero M, Oliver A, Sorli L, Luque S, Gomez-Zorrilla S, et al. Epidemiology and treatment?of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev?2019;32:e00031-19.?
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant,?extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim?standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, et al. P. aeruginosa bloodstream?infections among hematological patients: an old or new question? Ann Hematol 2012;91:1299-304.
Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, et al. Multidrug resistant Pseudomonas?aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation.?Haematologica 2010;95:1612-5.?
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and?development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.?Lancet Infect Dis 2018;18:318-27.?
Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections due to MDR gram-negative bacteria.?Front Med (Lausanne) 2019;6:74.?
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. IDSA guidance on the treatment?of antimicrobial-resistant gram-negative infections: version 1.1 [Internet]. Arlington: Infectious Diseases?Society of America; 2022 [cited 2022 Oct 25]. Available from: https://www.idsociety.org/practice-guideline/amr-guidance/.?
Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A.?baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based?on the mechanisms of resistance to carbapenems. Infection 2020;48:835-51.?
Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, et al. Analysis of the clinical pipeline of?treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob?Agents Chemother 2022;66:e0199121.?
Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob?Chemother 2017;72:1386-95.?
Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a?novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 2014;74:31-51.?
Hakeam HA, Askar G, Al Sulaiman K, Mansour R, Al Qahtani MM, Abbara D, et al. Treatment of?multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: a multicenter retrospective study. J Infect Public Health 2022;15:1081-8.?
Merck Sharp & Dohme LLC. Product information. Zerbaxa (ceftolozane-tazobactam) [Internet]. Rahway:?Merck Sharp & Dohme LLC; 2022 [cited 2022 Sep 22]. Available from: https://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf.?
※ AI-Helper는 부적절한 답변을 할 수 있습니다.